VANI

1.1404.59%
LE

Lisa E. Porter

Chief Medical Officer

Dr. Lisa E. Porter, M.D., serves as Chief Medical Officer at Vivani Medical, Inc. since 2022. Dr. Porter was Director at ViaCyte, Inc. since January 2022 until September 2022. Dr. Porter was Chief Medical Officer at Second Sight Medical Products, Inc. since January 2020. Dr. Porter had served as Chief Medical Officer of Metabolic Diseases at Eiger BioPharmaceuticals, Inc., since May 2018 until June 2019. Dr. Porter served as Senior Vice President of Metabolic Diseases at Eiger BioPharmaceuticals, Inc. since June 16, 2017 until May 2018. Dr. Porter served as Chief Medical Officer of Dance BioPharm Inc. since January 2014. From June 2013 to January 2014, Dr. Porter served as Consultant for Medical Affairs on a part-time basis at Dance BioPharm Inc. Dr. Porter has extensive experience in developing medicines for diabetes and metabolic diseases with a singular focus on bringing innovative therapies to patients with high unmet need. She served as a Consultant for Bristol-Myers Squibb from February 2013 to December 2013 and Prothena Biosciences Inc. from June 2013 to November 2013. From September 2004 to February 2013, she served as Vice President of Clinical Development/Medical Developing of Amylin Pharmaceuticals, LLC, where she led the R&D efforts for the Amylin-Lilly Alliance culiminating in the approval of the GLP-1 agonist Bydureon, the first once weekly treatment for Type 2 diabetes. From 1999 to 2004, Dr. Porter held progressively increasing leadership positions at GlaxoSmithKline Pharmaceuticals with responsosibilities for the clinical strategy for Avandia diabetes treatment and early obestiy compounds. Prior to joining Amylin Pharmaceuticals, she served in various positions with GlaxoSmithKline Pharmaceuticals and its predecessor, SmithKline Beecham Pharmaceuticals, since 1999, most recently as Group Director of Metabolism, Clinical Development and Medical Affairs from 2002 to 2004 and Senior Director of Metabolism for North American Medical Affairs from 2001 to 2004. Prior to joining GlaxoSmithKline, She previously served as Associate Medical Director of Endo-Oncology, Zeneca Pharmaceuticals from 1997 to 1999. Dr. Porter received her B.S. in Biology from College of William and Mary, M.D. from Duke University School of Medicine at Duke University and completed a fellowship training in Endocrinology and Metabolism/Hypertension at Brigham & Womens Hospital/Harvard Medical School.

公司职务